Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug 20;126(8):1033-40.
doi: 10.1182/blood-2015-04-639831. Epub 2015 Jun 30.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

Stefan O Ciurea  1 , Mei-Jie Zhang  2 , Andrea A Bacigalupo  3 , Asad Bashey  4 , Frederick R Appelbaum  5 , Omar S Aljitawi  6 , Philippe Armand  7 , Joseph H Antin  7 , Junfang Chen  8 , Steven M Devine  9 , Daniel H Fowler  10 , Leo Luznik  11 , Ryotaro Nakamura  12 , Paul V O'Donnell  5 , Miguel-Angel Perales  13 , Sai Ravi Pingali  1 , David L Porter  14 , Marcie R Riches  15 , Olle T H Ringdén  16 , Vanderson Rocha  17 , Ravi Vij  18 , Daniel J Weisdorf  19 , Richard E Champlin  1 , Mary M Horowitz  8 , Ephraim J Fuchs  11 , Mary Eapen  8
Affiliations

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

Stefan O Ciurea et al. Blood. .

Abstract

We studied adults with acute myeloid leukemia (AML) after haploidentical (n = 192) and 8/8 HLA-matched unrelated donor (n = 1982) transplantation. Haploidentical recipients received calcineurin inhibitor (CNI), mycophenolate, and posttransplant cyclophosphamide for graft-versus-host disease (GVHD) prophylaxis; 104 patients received myeloablative and 88 received reduced intensity conditioning regimens. Matched unrelated donor transplant recipients received CNI with mycophenolate or methotrexate for GVHD prophylaxis; 1245 patients received myeloablative and 737 received reduced intensity conditioning regimens. In the myeloablative setting, day 30 neutrophil recovery was lower after haploidentical compared with matched unrelated donor transplants (90% vs 97%, P = .02). Corresponding rates after reduced intensity conditioning transplants were 93% and 96% (P = .25). In the myeloablative setting, 3-month acute grade 2-4 (16% vs 33%, P < .0001) and 3-year chronic GVHD (30% vs 53%, P < .0001) were lower after haploidentical compared with matched unrelated donor transplants. Similar differences were observed after reduced intensity conditioning transplants, 19% vs 28% (P = .05) and 34% vs 52% (P = .002). Among patients receiving myeloablative regimens, 3-year probabilities of overall survival were 45% (95% CI, 36-54) and 50% (95% CI, 47-53) after haploidentical and matched unrelated donor transplants (P = .38). Corresponding rates after reduced intensity conditioning transplants were 46% (95% CI, 35-56) and 44% (95% CI, 0.40-47) (P = .71). Although statistical power is limited, these data suggests that survival for patients with AML after haploidentical transplantation with posttransplant cyclophosphamide is comparable with matched unrelated donor transplantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Nonrelapse mortality. (A) The cumulative incidence of nonrelapse mortality by donor type after myeloablative conditioning regimen, adjusted for performance score. (B) The cumulative incidence of nonrelapse mortality by donor type after reduced intensity conditioning regimen, adjusted for disease risk index.
Figure 2
Figure 2
Relapse. (A) The cumulative incidence of relapse by donor type after myeloablative conditioning regimen, adjusted for disease risk index. (B) The cumulative incidence of relapse by donor type after reduced intensity conditioning regimen, adjusted for performance score, disease risk index, and secondary AML.
Figure 3
Figure 3
Overall survival. (A) The probability of OS by donor type after myeloablative conditioning regimen, adjusted for age and disease risk index. (B) The probability of OS by donor type after reduced intensity conditioning regimen, adjusted for disease risk index and secondary AML.
See this image and copyright information in PMC

References

    1. Appelbaum FR. Hematology Am Soc Hematol Educ Program. 2008. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia when a matched related donor is not available. pp. 2008:412–417. - PubMed
    1. Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012;119(17):3908–3916. - PMC - PubMed
    1. Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood. 2004;104(9):2976–2980. - PubMed
    1. Switzer GE, Bruce JG, Myaskovsky L, et al. Race and ethnicity in decisions about unrelated hematopoietic stem cell donation. Blood. 2013;121(8):1469–1476. - PMC - PubMed
    1. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339–348. - PMC - PubMed

Publication types